Interferon-α therapy in HBeAg-negative chronic hepatitis B: A long-term prospective study from north-western Greece

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 3, 2006, Pages 525-533

  Baltayiannis, G ^a   Katsanos, K ^a   Karayiannis, P ^b   Tsianos, E V ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; AGED; ARTICLE; CHEMICAL ANALYSIS; CHI SQUARE TEST; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DRUG RESPONSE; FEMALE; FOLLOW UP; GREECE; HEPATITIS B; HISTOLOGY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONITORING; MULTIVARIATE ANALYSIS; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SURVIVAL; VIROLOGY;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GREECE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33745905308     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03008.x     Document Type: Article

References (36)

1. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001; 120: 1828-53.
2. Chan HL, Leung NW, Hussain M, et al. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31: 763-8.
3. Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepatitis Reviews 1995; 1: 7-15.
4. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-91.
5. Brunetto MR, Stemler M, Schodel F, et al. Identification of HBV variants which cannot produce precore derived HbeAg and may be responsible for severe hepatitis. Ital J Gastroenterol 1989; 21: 151-4.
6. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-53.
7. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263-70.
8. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 306-13.
9. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 101-9.
10. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-9.
11. Lok Anna SF, McMahon Brian J. Chronic hepatitis B. Hepatology 2001; 34: 1225-41.
12. Di Marco V, Lo Iakono O, Camma C, et al. The long-term course of chronic hepatitis B. Hepatology 1999; 30: 257-64.
13. Weissberg JI, Andres LL, Smith CI, et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 1984; 101: 613-6.
14. De Jongh FE, Janssen HLA, De Man RA, et al. Survival and prognostic indicators in HBsAg-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-5.
15. Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 1994; 21: 656-66.
16. Lampertico P, Del Ninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of interferon-2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26: 1621-5.
17. Oliveri F, Santantonio T, Bellati G, et al. Long term response to therapy of chronic anti-HbeAg positive hepatitis B is poor independent of type and schedule of interferon. Am J Gastroenterol 1999; 94: 1366-72.
18. Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995; 1: 7-36.
19. Brunetto MR, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989; 10: 198-202.
20. Fattovich G, Farci P, Rugge M, et al. A randomized controlled trial of lymphoblastoid interferon-α in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992; 15: 584-9.
21. Hadziyiannis S, Bramou T, Makris A, et al. Interferon alfa-2b treatment of HbeAg negative/serum HBV DNA positive chronic active hepatitis B. J Hepatol 1990; 11: S133-6.
22. Pastore G, Santantonio T, Milella M, et al. Anti-HBe-positive Chronic Hepatitis B with HBV-DNA in the serum: response to a 6-month course of lymphoblastoid interferon. J Hepatol 1992; 20: 221-5.
23. Villa E, Rubbiani L, Barchi T, et al. Susceptibility of chronic symptomless HBsAg carriers to ethanol-induced hepatic damage. Lancet 1982; II: 1243-4.
24. Chevillotte G, Durbec JP, Gerolami A, et al. Interaction between hepatitis B virus and alcohol consumption in liver cirrhosis. An epidemiologic study. Gastroenterology 1983; 85: 141-5.
25. Hadziyannis SJ. Interferon alpha therapy in HbeAg-negative chronic hepatitis B: new data in support of long-term efficacy. J Hepatol 2002; 36: 280-2.
26. Kao J-H, Wu N-H, Chen P-J, et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998-1002.
27. Ze L, Tarn HG, Ming YP, et al. Correlation of HBV DNA levels in serum and liver of chronic hepatitis B patients with cirrhosis. Liver 2002; 22: 130.
28. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
29. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
30. Feinman SV, Berris B, Sooknanan R, et al. Effects of interferon-alpha therapy on serum and liver HBV DNA in patients with chronic hepatitis B. Dig Dis Sci 1992; 37: 1477-82.
31. Ohkubo K, Kato Y, Ichikawa T, et al. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer 2002; 94: 2663-8.
32. Ikuo N, Giuseppe C, Gregorio Germana V, et al. The role of HBV DNA quantitative PCR in monitoring the response to interferon treatment in chronic hepatitis B infection. J Hepatol 1999; 30: 965-9.
33. Simon K, Rotter K, Zalewska M, et al. HBV-DNA level in blood serum as a predictor of good response to therapy with interferon-alpha-2b of patients with chronic hepatitis B. Med Sci Monit 2000; 6: 971-5.
34. Dalekos GN, Galanakis E, Zervou E, et al. Interferon-alpha treatment of children with chronic hepatitis D virus infection: the Greek experience. Hepatogastroenterology 2000; 47: 1072-6.
35. Dalekos GN, Hatzis J, Tsianos EV. Dermatologic disease during interferon-alpha therapy for chronic viral hepatitis. Ann Intern Med 1998; 128: 409-10.
36. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002; 9: 52-61.